Alar Pharmaceuticals Inc.

Taipei Exchange 6785.TWO

Alar Pharmaceuticals Inc. Price to Sales Ratio (P/S) on January 14, 2025: 17.54

Alar Pharmaceuticals Inc. Price to Sales Ratio (P/S) is 17.54 on January 14, 2025, a -29.38% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Alar Pharmaceuticals Inc. 52-week high Price to Sales Ratio (P/S) is 29.31 on August 30, 2024, which is 67.13% above the current Price to Sales Ratio (P/S).
  • Alar Pharmaceuticals Inc. 52-week low Price to Sales Ratio (P/S) is 16.67 on January 13, 2025, which is -4.93% below the current Price to Sales Ratio (P/S).
  • Alar Pharmaceuticals Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 22.94.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Taipei Exchange: 6785.TWO

Alar Pharmaceuticals Inc.

CEO Dr. Yung-Shun Wen Ph.D.
IPO Date Oct. 5, 2020
Location
Headquarters No. 32, Keya Road
Employees 22
Sector Health Care
Industries
Pharmaceuticals Clinical Trials
Description

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson's disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email